BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cancer Drug Spinoff of Australian Company, Audeo Oncology Inc. Preps $49 Million IPO


12/10/2012 8:47:03 AM

An Australian import to San Francisco plans to raise $49 million in an initial public offering to fuel late-stage development of its experimental cancer-targeting drug. Audeo Oncology Inc., incorporated in June as part of a reorganization of the publicly traded Australian company Alchemia Ltd., priced its IPO of 3.25 million shares at $14-16 per share. It will trade starting next week on the NASDAQ global exchange as "AURX." It is one of two IPOs planned by Bay Area companies next week. The other is San Mateo-based SolarCity Corp.'s $141 million offering; it will be traded on NASDAQ as "SCTY." Soon after Audeo's IPO, the company will demerge from Alchemia, with that company's shareholders receiving one common share of Audeo for every 37 ordinary shares of Alchemia. The move should benefit current Alchemia backers like Allan W.B. Gray and his Orbis Investment Management Ltd., according to the Sydney Morning Herald. Gray invested $21 million in Alchemia last year, according to the newspaper, and would control about 13 percent of Audeo after the demerger, according to a Securities and Exchange Commission filing. Audeo lost $10 million in the fiscal year ended June 30 and had an accumulated deficit of about $47.1 million as of Sept. 30. Audeo's Phase III drug combines the chemotherapy agent ireinotecan with what it calls "hyaluronic acid chemotransport technology," or HYACT, to target metastatic colorectal cancer. The technology helps existing chemotherapy agents zero in on tumor cells, the company said in an SEC filing, lowering chemo's toxic side effects.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES